Charles Schwab Investment Management Inc Bio Xcel Therapeutics, Inc. Call Options Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BTAI
# of Institutions
77Shares Held
6.6MCall Options Held
85KPut Options Held
221K-
Black Rock Inc. New York, NY1.33MShares$1.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.1MShares$1.41 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN579KShares$741,3290.0% of portfolio
-
State Street Corp Boston, MA465KShares$595,0820.0% of portfolio
-
Geode Capital Management, LLC Boston, MA458KShares$586,1370.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $35.9M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...